HomeEmtricitabine And Tenofovir Disoproxil FumarateEmtricitabine And Tenofovir Disoproxil Fumarate + Didanosine

Does Emtricitabine And Tenofovir Disoproxil Fumarate Interact with Didanosine?

Emtricitabine And Tenofovir Disoproxil Fumarate and Didanosine have a major drug interaction according to U.S. FDA drug labeling data. Tenofovir disoproxil fumarate increases didanosine concentrations. Close monitoring for didanosine toxicity is warranted; dose reduction recommended for patients >60 kg. The mechanism involves increased didanosine concentrations due to tenofovir interaction. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Emtricitabine And Tenofovir Disoproxil Fumarate Class
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Emtricitabine And Tenofovir Disoproxil Fumarate and Didanosine occurs because increased didanosine concentrations due to tenofovir interaction. Clinically, this means tenofovir disoproxil fumarate increases didanosine concentrations. close monitoring for didanosine toxicity is warranted; dose reduction recommended for patients >60 kg. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Emtricitabine And Tenofovir Disoproxil Fumarate and your doctor is considering prescribing Didanosine (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Emtricitabine And Tenofovir Disoproxil Fumarate(Emtricitabine And Tenofovir Disoproxil Fumarate)+💊 Didanosine

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Drug B class
Source
NLP:emtricitabine and tenofovir disoproxil fumarate

What this means in plain English

Tenofovir disoproxil fumarate increases didanosine concentrations. Close monitoring for didanosine toxicity is warranted; dose reduction recommended for patients >60 kg.

What the FDA label says

"Increased didanosine concentrations due to tenofovir interaction"

📖 Source: NLP:emtricitabine and tenofovir disoproxil fumarate

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Emtricitabine And Tenofovir Disoproxil Fumarate and Didanosine against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.